# Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

> **NCT06842407** · — · RECRUITING · sponsor: **Checkmab S.r.l.** · enrollment: 600 (estimated)

## Conditions studied

- Healthy Donors

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06842407
- **Lead sponsor:** Checkmab S.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06842407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06842407, "Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06842407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*